Tuesday, November 02, 2021 7:33:38 AM
http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent
http://www.ipharminc.com/press-release/2021/10/25/innovation-pharmaceuticals-covid-19-clinical-trial-topline-results-anticipated-to-be-reported-the-week-of-november-8th
Be careful with this, the clock runs fast, pay attention to the week of November 8 or even earlier
http://www.ipharminc.com/press-release/2021/10/25/innovation-pharmaceuticals-covid-19-clinical-trial-topline-results-anticipated-to-be-reported-the-week-of-november-8th
Be careful with this, the clock runs fast, pay attention to the week of November 8 or even earlier
Recent GILD News
- FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) • Business Wire • 05/22/2026 06:00:00 PM
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors • Business Wire • 05/22/2026 11:47:00 AM
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology • Business Wire • 05/21/2026 09:00:00 PM
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio • Business Wire • 05/21/2026 01:30:00 PM
- Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease • Business Wire • 05/21/2026 07:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:15:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 08:15:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:09:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:07:18 PM
- Gilead Prices $3 Billion of Senior Unsecured Notes • Business Wire • 05/15/2026 01:21:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/14/2026 09:11:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2026 12:46:00 PM
- Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 • Business Wire • 05/13/2026 12:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/08/2026 09:00:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:13:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:12:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:01 PM
- Gilead Sciences Announces First Quarter Financial Results • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:40:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:36:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:31:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:28:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:25:01 PM
